Chlitina Holding Chairwoman Chen Pi-hua (second from left) and U-NEURON Chairman Dr. Frank Chien (second from right) announce their partnership to capture the anti-aging market.

Chlitina Targets International Markets with Anti-Aging Opportunities - 永立榮生醫
Chlitina Targets International Markets with Anti-Aging Opportunities

(Photo courtesy of Chlitina) Chlitina Holding (4137) is ramping up its investments in Taiwan by joining forces with U-NEURON Biomedical (6973) to target the anti-aging market.

Their first joint product line—the “Origin Secret” skincare series featuring deer amniotic fluid extract—made its debut on January 3. Chlitina Chairwoman Chen Pi-hua stated that a full-scale advertising campaign for the line will launch in May, with plans to expand back into Mainland China as early as Q3 while accelerating its global layout.

In 2023, Chlitina was awarded a spot among the “Top 25 Best Taiwan Global Brands” for the eighth time with a brand value of US$94 million (approximately NT$3 billion), making it the only beauty and skincare brand to achieve this recognition. In the first 11 months of 2023, Chlitina reported revenue of NT$4.142 billion—an 8.47% year-on-year increase—with earnings per share (EPS) reaching NT$9.25 in the first three quarters. Institutional investors project full-year earnings for 2023 to exceed NT$10 per share.

For 2024, supported by aggressive investments in Taiwan and efforts to boost brand visibility, analysts remain optimistic that Chlitina will sustain its growth curve in both revenue and profitability.

U-NEURON’s “Deer Amniotic Fluid Extract D-AFER” has beenregisteredunderthe International Nomenclature of Cosmetic Ingredients(INCI),theingredientnaming system recognized in markets including the United States, the European Union, Japan, and South Korea.

In Taiwan, this product line will be launched through Chlitina’s subsidiary distribution channel, KindShare. Chen Pi-hua noted that the pandemic reshaped sales channel paradigms, fueling steady growth in low-cost direct selling models. Chlitina’s strategy in Taiwan uses direct selling and cross-industry alliances as its spearhead. KindShare, Chlitina’s product distribution venture launched in 2023, centers on sustainable co-existence. Its R&D focuses on three core pillars: water, micro-ecology, and regenerative medicine—covering personal care, nutritional supplements, and anti-aging products to build an operational advantage via medical and direct sales channels.

In addition to natural alkaline water, 100%-owned KindShare currently distributes the P113+ oral care series (patented by GeneReach). The “Origin Secret” series, unveiled on January 3 in partnership with U-NEURON, emphasizes fine skin texture, skin repair, and wrinkle reduction. Over 80% of distributors at the product launch event placed orders on the spot, surpassing 500 sets in volume.

Chen reflected that she has completed the first chapter of her career, having spent 27 years building a medical aesthetics empire in Mainland China, where her flagship brand “CHLITINA” now operates 5,000 locations—the largest network globally.

In the second chapter of her career, she is shifting her focus toward the anti-aging health industry using a fresh strategic approach. Chen emphasized that KindShare follows a “small investment, steady happiness” strategy. As long as product quality remains high, the Taiwan business is positioned for exponential growth. Beyond making “Origin Secret” a cornerstone skincare launch in 2024, the company plans to expand into retail stores to deepen its footprint in Taiwan’s healthcare and personal care markets.

Source:https://www.ctee.com.tw/news/20240104700226-439901

2024.01.04 Industrial and Commercial Times Commercial Times / Reporter Hui-Jung Tu (January 4, 2024)